Sign up USA
Proactive Investors - Run By Investors For Investors

Theralase to expand bladder cancer trial after initial success

Theralase's Photo Dynamic Therapy technology is a "search and destroy" treatment for cancer cells
Bladder pain
The primary and secondary objectives for the first part of the non-muscle invasive bladder cancer clinical study were successfully met

The first part of cold laser technology firm Theralase Technologies Inc’s (CVE:TLT) phase Ib bladder cancer trial has gone well.

The primary and secondary objectives for the first part of the non-muscle invasive bladder cancer (NMIBC) clinical study were successfully met, the independent data and safety monitoring board unanimously determined.

The plan now is to sign-up another six patients for the second part of the study, in which they will be treated with a therapeutic dose of the photo dynamic compound (PDC) for NMIBC using Theralase’s photo dynamic therapy (PDT) technology.

READ Laser specialist TheraLase Technologies primed for a pivotal year

"I am delighted that a small Canadian company, such as Theralase, has been able to achieve such significant clinical results and in such a short time span. I look forward to Theralase reporting out on the next six patients using the therapeutic dose," said Dr Michael Jewett, uro-oncologist at the University Health Network.

Theralase’s boss and founder, Roger Dumoulin-White, thanked the data and safety monitoring board for performing the review.

“Theralase looks forward to successfully reporting out on the performance to the primary and secondary endpoints for the next six patients and also the exploratory objective of efficacy of all nine patients, as more clinical data is collected,” Dumoulin-White said.

“Theralase has now successfully transformed from a pre-clinical to a clinical oncology organization,” he added.

View full TLT profile View Profile

Theralase Technologies Inc. Timeline

Related Articles

An illustration of the tools Velpic uses in providing education and incident management
March 22 2018
Velpic has just signed its first NowForce client in Australia.
1515684629_Universal-mCloud-pic-1.jpg
January 11 2018
Universal mCloud's technology set services some of the biggest companies in the world
1510629376_Agent-Reality-and-Sweep.JPG
November 15 2017
Thred's Geoff Marshall at Proactive's CEO Sessions in Melbourne and Sydney.
Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use